Remedies and merger control (Paris, April 20th 2012)

The question of remedies, their design, their effectiveness, their implementation and their monitoring is a challenging issue for both the competition authorities and merging companies. The articles in this issue transcribe some interventions made at the recent conference organized by CompetitionRx and Microeconomix.

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. Introductory Remarks Gildas of Muizon Economist and Associate Director, Microeconomix 1. What's new since the study on remedies published by the European Commission in October 2005? This study showed that behavioural commitments were frequently used despite the reservations expressed about them, particularly in terms of their effectiveness. It also showed that the ex-post effectiveness of the remedies was found to be poor or even bad. The questionable choice and rough monitoring of proxies is one of the reasons pointed out by the study for this situation. 2. There is no doubt that significant progress has been made over the past seven years. According to

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.


PDF Version


  • Added Value Capital Partners (AVCP) (Royston)
  • Analysis Group (Paris)
  • Deloitte (Paris)
  • Mazars (Brussels)


Matthew Gaved, Emmanuel Frot, Gildas de Muizon, Justin Menezes, Remedies and merger control (Paris, April 20th 2012), September 2012, Concurrences N° 3-2012, Art. N° 48162,

Visites 653

All reviews